|Present||Associate Professor, Philadelphia College of Osteopathic Medicine ‐ Department of Pharmaceutical Sciences|
|2012 - 2013||Angiotensin II and glutamate additively or synergistically disrupt the intracellular Ca2+ homeostasis of astroglia|
|2010 - 2011||Dually Targeting L-type Ca2+ Channel and Type 4 Phosphodiesterase for Treatment of Obesity|
|2008 - 2009||Mechanism of cardiac protective effect of inhibitors of late sodium current|
|CV Therapeutics, Inc|
|2005 - 2007||Ambient particulate matters poison cardiac ion channels|
|2004 - 2005||No Title|
|Cancer Complementary and Alternative Medicine Center at University of South Carolina|
|Role: PI, Project #4|
|2001 - 2004||Effects of Dioxins (TCDD) on Cardiac ion Channels|
Professional Service and Affiliations
|Member, AP&S Committee of PCOM School of Pharmacy||Member, American Association of Colleges of Pharmacy||Council on Basic Cardiovascular Sciences, American Heart Association||Council on High Blood Pressure Research, American Stroke Association||Member, Curriculum Committee of PCOM School of Pharmacy||Member, PCOM Appointment, Promotion and Tenure Committee||Member, PCOM Student Academic Progress & Policy Committee|
Honors and Awards
- Researcher of the Year, USC College of Pharmacy, 2005
- NIH Merit Award, for helping to publish CEHP journal by NIEHS/NIH, 2001
- Transition to Independent Position Award, NIEHS/NIH, 2000
- 2000 Fare Award, National Institute of Health, 1999
- Research Fellowship, American Heart Association, 1995
- Outstanding Student of University of Florida, 1994
- Procter & Gamble Professional Opportunity Award, Am. Physiol. Society, 1993
- Elite Young Researcher Award, Chinese Physiological Society, 1988
- Integrated Therapeutics III (PHAR 213G)
- Integrated Therapeutics II (PHAR 212G)
- Integrated Therapeutics I (PHAR 211G)
- Physiology and Pathophysiology I (PHAR 113G)
- Anatomy Lab ((PHAR 112G)
- Anatomy (PHAR 110g)
|1995||PhD, University of Florida ‐ Pharmacology|
|1985||MS, Shanxi Medical University ‐ Neuroscience|
|1982||BS, Shanxi Medical University ‐ Medicine|
Scholarly & Professional Articles (15)
Preclinical pharmacokinetics and metabolism of MNP001, a piperidine analog of ...
Biopharmaceutics and Drug Disposition (2011)
MNP001 is a newly synthesized 3-carbamyl-4-methylpyrrole analog with dual pharmacophores simultaneously to inhibit phosphodiesterase type 4 (PDE4) and to antagonize ...
HPLC/MS/MS analysis of 3-carbamyl-4-methylpyrrole analog MNP001, a highly ...
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences (2009)
Chemically synthesized 3-carbamyl-4-methylpyrroles were characterized as a group of antihypertensive agents with dual-targeting mechanism to simultaneously inhibit type 4 phosphodiesterase ...
The comparison study on effects of water-soluble components of fine ...
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] (2008)
OBJECTIVE: To compare the difference of vasomotor functions in aortas segments from Wistar rats between 1-hour and 6-hours after exposure ...
High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 ...
Journal of pharmaceutical and biomedical analysis (2006)
MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase ...
Validation of HPLC analysis method of a novel antihypertensive agent ...
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences (2006)
MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. ...